Discussion
The Phase 3 BEACON clinical trial, which is testing the experimental therapy rugonersen in people with Angelman syndrome, has begun dosing participants. Oak Hill Bio, the company developing rugonersen and sponsoring the trial, announced that the first participant had been dosed in late July. The trial is currently…